logo-loader

Genprex Inc retains pharmaceutical branding company to commercialize its lung cancer drug

Last updated: 09:29 08 May 2019 EDT, First published: 09:11 08 May 2019 EDT

Oncoprex name tag
The clinical-stage gene therapy company has developed a non-small cell lung cancer treatment, currently called Oncoprex

Genprex Inc (NASDAQ:GNPX) has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

The clinical-stage gene therapy company has developed the drug to treat non-small cell lung cancer treatment.

Addison Whitney will oversee the official naming process, which requires regulatory approval.

READ: Genprex reports positive preclinical data on its drug to treat lung cancer

"Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Chairman and CEO Rodney Varner said. "Obtaining regulatory approval of proprietary and non-proprietary drug names is a necessary step in securing marketing approval, and Addison Whitney has an impressive track record in obtaining such name approvals.”

The Austin-based company’s drug fights non-small cell lung cancer by transporting cancer-fighting genes to cancerous cells.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

8 hours, 44 minutes ago